Medicine and Health Sciences Commons^™

P53 And Vegf Expression In Human Temporomandibular Joint Discs With Internal Derangement Correlate With Degeneration, Sergio Castorina, C. Lombardo, Paola Castrogiovanni, Giuseppe Musumeci, E. Barbato, Luis Eduardo Almeida, Rosalia Leonardi

School of Dentistry Faculty Research and Publications

No abstract provided.

Immunohistochemical Analysis Of Il-1 Beta In The Discs Of Patients With Temporomandibular Joint Dysfunction, Luis Eduardo Almeida, Sean Pierce, Joseph Zacharias, William E. Cullinan, Lucia Noronha, Marcia Olandoski, Vinicius Tramontina, Carla Loreto, Rosalia Leonardi

School of Dentistry Faculty Research and Publications

Purpose: Interleukin-1 beta (IL-1β) is a cytokine that participates in the regulation of immune responses and inflammatory reactions. It is hypothesized that IL-1 levels may be elevated in patients suffering from temporomandibular joint dysfunction. The purpose of this study was to determine the association of IL-1β expression with TMD using an immunohistochemical approach to evaluate the joint disc.

Materials and methods: A total of 39 human temporomandibular joint disc samples were collected, with 31 samples in the test group. Nineteen of the test group samples were from discs of patients with anterior disc displacement with reduction, and 12 …

Adam10 Localization In Temporomandibular Joint Disk With Internal Derangement: An Ex Vivo Immunohistochemical Study, Carla Loreto, Giovanni Paolo Salvatore Chiarenza, Giuseppe Musumeci, Paola Castrogiovanni, Rosa Imbesi, Alessandra Ruggeri, Luis Eduardo Almeida, Rosalia Leonardi

School of Dentistry Faculty Research and Publications

The purpose of this study was to determine the presence of ADAM10 in temporomandibular joint disk with internal derangement. Twenty-five paraffin blocks of displaced temporomandibular joint (TMJ) disk specimens from earlier investigations were retrieved from the archives of the University of Catania. Of these 16 had been removed from females and 9 from males; 11 with anterior disk displacement with reduction (ADDwR) and 14 with anterior disk displacement without reduction (ADDwoR). The sections were dehydrated, embedded in paraffin and cut. Then they were incubated in 0.3% H₂O₂/methanol and half of sections from each sample were incubated …

Hierarchical Cluster Analysis Of Myoepithelial/Basal Cell Markers In Adenoid Cystic Carcinoma And Polymorphous Low-Grade Adenocarcinoma, Manju L. Prasad, Catalin C. Barbacioru, Yeshwant B. Rawal, Omar Husein, Ping Wen

School of Dentistry Faculty Research and Publications

Distinguishing adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma of the salivary glands is important for their management. We studied the expression of several myoepithelial and basal/stem cell markers (smooth muscle actin, calponin, smooth muscle myosin heavy chain, metallothionein, maspin, and p63) by immunohistochemistry in 23 adenoid cystic carcinoma and 24 polymorphous low-grade adenocarcinoma, to identify the most useful marker or combination of markers that may help their diagnoses. The results were analyzed using hierarchical cluster analysis and χ² test for trend. We noted diffuse expression of smooth muscle actin in 20 adenoid cystic carcinoma vs one polymorphous low-grade adenocarcinoma …

The Absence Of Cd20 Messenger Rna In Recurrent Cutaneous B-Cell Lymphoma Following Rituximab Therapy, Yeshwant B. Rawal, Gerard J. Nuovo, Gwyn E. Frambach, Pierluigi Porcu, Robert A. Baiocchi, Cynthia M. Magro

School of Dentistry Faculty Research and Publications

Background: Rituximab has been used to treat relapsed low-grade or advanced non-Hodgkin's lymphoma since 1997, targeting the CD20 antigen expressed by B cells. Single-agent rituximab therapy is safe and well tolerated. Recurrences showing a loss of CD20 expression following rituximab therapy have been reported.

Methods: Four patients with CD20-positive cutaneous B-cell lymphoma received rituximab therapy with subsequent recurrences. The biopsies were assessed for cytoplasmic CD20 expression; CD20 messenger RNA was also assessed where tissue was available.

Results: Cutaneous relapses occurring within 1.5–3 months following the last dose of rituximab were CD20 negative. In three cases, subsequent relapses showed renewed expression …